Results 151 to 160 of about 1,377,243 (284)

Efficacy and Safety of Once‐Weekly Semaglutide 2.0 mg as an Add‐On to Dose‐Reduced Insulin Glargine versus Dose‐Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE)

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9304-9316, October 2026.
ABSTRACT Aims Type 2 diabetes (T2D) management with basal insulin can lead to hypoglycaemia and weight gain. SUSTAIN OPTIMIZE compared once‐weekly semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine (Sema+IGlarreduced) versus dose‐titrated IGlar (IGlartitrated) on glycated haemoglobin (HbA1c), body weight (BW), daily insulin dose, and ...
Helena W. Rodbard, Concetta Irace, Jevitha Lobo, Konstantinos Makrilakis, Prachi Priyadarshini, Suvanjaa Sivalingam, Santiago Tofé Povedano, Anuj Bhargava   +7 more
wiley   +1 more source

A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra‐Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9423-9432, October 2026.
ABSTRACT Aims To evaluate the pharmacokinetics, pharmacodynamics, and safety of a novel U500 insulin aspart formulation (AT278 [500 U/mL]; AT278‐U500) compared with standard concentration insulin aspart (InsAsp [100 U/mL]; InsAsp‐U100) and U500 human regular insulin (HumIns [500 IU/mL]; HumIns‐U500). Materials and Methods This single‐centre, randomised,
Eva Svehlikova, Christina Gatschelhofer, Bettina Lackner, Maria Ratzer, Gabriele Fluhr, Anja Stoisser, Gregor Kolaric, David Gerring, Sarah Howell, Jan Jezek, Fiona Lawrence, Thomas R. Pieber   +11 more
wiley   +1 more source

Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real‐World National Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9633-9643, October 2026.
ABSTRACT Aims Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real‐world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Estelle Audrain, Pierre Bel Lassen, Christine Bellanné‐Chantelot, Marie Christine Vantyghem, Hippolyte Dupuis, Tiphaine Vidal‐Trecan, Nicolas Chevalier, Danièle Dubois‐Laforgue, Sophie Lamothe, Camille Vatier, Orianne Villard, René Valéro, Claire Briet, Corinne Vigouroux, Cécile Ciangura, Chloé Amouyal   +15 more
wiley   +1 more source

Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second‐Line Antidiabetic Drugs

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9655-9667, October 2026.
ABSTRACT Objective To examine the effect of second‐line treatments (insulin secretagogues, thiazolidinediones, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors) on time to insulin initiation among patients with type 2 diabetes.
Ya‐Hui Yu, Qi Zhang, Estefania Zapata‐Bravo, Robert W. Platt, Pauline Reynier, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source

The Development of Sulfonylurea Compounds

Hans Journal of Medicinal Chemistry, 2014
openaire   +1 more source

Nanomedicine for the Treatment of Pediatric Type 2 Diabetes: Progress, Challenges, and Translational Perspectives

Advanced Therapeutics, Volume 9, Issue 9, September 2026.
Overview of pharmaceutical nanocarriers in diabetes, illustrating applications of nanotechnology including enhanced drug and targeted drug delivery and nanosensors for glucose monitoring and diagnosis. ABSTRACT Pediatric type 2 diabetes mellitus (T2DM) is rapidly emerging as a critical global health concern, driven largely by rising childhood obesity ...
Nnamdi Ikemefuna Okafor, Bukosi Baloyi, Yahya E. Choonara   +2 more
wiley   +1 more source

Discovery of novel quinazoline-sulfonamide derivatives with promising antidiabetic activity. [PDF]

Front Chem
Zayed MF, Muhammad Y, Alqurain AA, Banafa MAA, Omar AM.   +4 more
europepmc   +1 more source

Type 5 Diabetes Mellitus: Pathophysiology, Clinical Phenotype, and Nutritional Management

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 6, September 2026.
ABSTRACT Type 5 Diabetes Mellitus (T5DM) is an emerging diabetes phenotype linked to chronic undernutrition. It predominantly affects young, lean individuals in low‐ and middle‐income countries. After its formal recognition by the International Diabetes Federation in 2025, T5DM resurfaced as a clinically relevant insulin‐deficient phenotype.
İrem Nur Şahin Anılgan, Aslıhan Atar‐Uğurlu   +1 more
wiley   +1 more source

Lead optimization of AMS-17 identifies AMS-4 as a modulator of inflammasome-driven cocaine-associated neuroinflammation. [PDF]

Biochem Biophys Res Commun
Singh S, Gupta NK, Ahsan AU, Oladapo A, Mata LO, Buch S, Kulkarni A, Periyasamy P.   +7 more
europepmc   +1 more source

Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
This prospective observational study evaluated changes in dietary patterns and body composition after 3 months of oral semaglutide treatment in people with Type 2 diabetes. Oral semaglutide was associated with reduced energy intake, salt intake and body fat while preserving handgrip strength.
Mika Sawada, Naoko Nakanishi, Masakazu Aihara, Kanako Ohkuma, Shoko Hamano, Yoshitaka Sakurai, Rie Sekine, Satoshi Usami, Toshimasa Yamauchi, Naoto Kubota   +9 more
wiley   +1 more source